E
Erwin W. Gelfand
Researcher at University of Colorado Denver
Publications - 679
Citations - 37565
Erwin W. Gelfand is an academic researcher from University of Colorado Denver. The author has contributed to research in topics: Immunoglobulin E & T cell. The author has an hindex of 99, co-authored 675 publications receiving 36059 citations. Previous affiliations of Erwin W. Gelfand include University of Colorado Hospital & University of Virginia.
Papers
More filters
Journal Article
Antibody-mediated target cell lysis by nonimmune cells: the use of anti-immunoglobulin to distinguish effector cell population.
TL;DR: The role of a goat IgG anti-rabbit immunoglobulin on antibody-mediated target cell lysis by nonimmune cells was investigated and the mechanism of enhancement appeared to be due to cross-linking between effector lymphocytes and antibody-coated target cells by the divalent anti-immunoglOBulin.
Journal Article
Heterogeneity of Human Thymocytes and a Malignant T-Lymphoblast Cell Line, MOLT-3
TL;DR: Analysis of the subpopulations of thymocytes demonstrated that they represent a heterogeneous population of cells with respect to their size, proliferative activity, and presence and quantities of terminal deoxynucleotidyl transferase and human thymus leukemia-associated antigen, a thymic isozyme of adenosine deaminase.
Journal ArticleDOI
Safety and tolerability of increased rate of infusion of intravenous immunoglobulin G, 10% in antibody-deficient patients.
Erwin W. Gelfand,Kim Hanna +1 more
TL;DR: Increasing the rate of infusion of IGIV-C, 10% by 75% up to 0.14 mL/kg/min (840 mg/ kg/h) was well tolerated, suggesting safe administration of IGiva, 10%, at this rate, and resulted in a shortened overall infusion time.
Journal ArticleDOI
A prostacyclin agonist with thromboxane inhibitory activity for airway allergic inflammation in mice.
Masachika Hayashi,Toshiyuki Koya,Hidenori Kawakami,Takurou Sakagami,Takashi Hasegawa,Hiroshi Kagamu,Toshinori Takada,Y. Sakai,Eiichi Suzuki,Erwin W. Gelfand,Fumitake Gejyo +10 more
TL;DR: The effect of ONO‐1301 on development of airway allergic inflammation is investigated and it is shown that the drug acts as a prostacyclin agonist with thromboxane A2 synthase inhibitory activity.
Journal ArticleDOI
Pretreatment with allergen prevents immediate hypersensitivity and airway hyperresponsiveness.
A. Oshiba,Eckard Hamelmann,Katherine Bradley,Joan E. Loader,Harald Renz,Gary L. Larsen,Erwin W. Gelfand +6 more
TL;DR: The data suggest that IgE (and IgG1) responses and airway hyperresponsiveness induced by allergen sensitization via the airways can be modulated by subcutaneous administration of peptide.